Orbimed Capital LLC

ORBIMED ADVISORS LLC (Director) purchased 2,815,315 shares for $12,499,998.60 at $4.44 on 2026-04-21

ORBIMED ADVISORS LLC, a Director, executed 2 separate purchases totaling 2,815,315 shares (2.82M shares) for $12,499,998.60 ($12.5M) at a blended average price of $4.44 on 2026-04-21. The transaction represents a substantial commitment: post-transaction holdings of 1,126,126 shares reflect a net increase from a pre-transaction position of -1,689,189 shares. The stock is currently trading at $4.40, only -20.3% from its 52-week high of $5.52 and up +41.0% over 30 days and +117.8% over 90 days. ORBIMED's cross-ticker track record shows strong performance on buys (5 prior buys with 100% 90-day win rate and +469.9% average 30-day return) against a more mixed record on sells (75% well-timed rate). Prelude Therapeutics remains unprofitable with quarterly revenue of $6,500,000 ($6.5M) and net income of $-19,725,000 ($-19.7M), though the company posted +73.4% annual revenue growth. The large capital commitment by a director at current valuations into an unprofitable but high-growth biotech company should be monitored against the company's path to profitability and execution on its pipeline.

Director ORBIMED ADVISORS LLC sold 83,695 shares of SPRY at $13.00 (total $1.1M), exiting entire position amid 4 consecutive sales in 3 days

ORBIMED ADVISORS LLC executed a complete exit of its 83,695 share stake in ARS Pharmaceuticals on 2024-08-26, realizing $1,088,035.00 at $13.00 per share. This transaction is the fourth in a concentrated sell sequence over three trading days (2024-08-21 through 2024-08-26), signaling a deliberate and rapid liquidation of the director's entire holding. The company's recent fundamentals are severely challenged: annual revenue growth contracted -97.7%, with the latest quarter generating only $500,000.00 in revenue against a full-year net loss of $-12,516,000.00. The rapid succession of sells—unfolding while the stock was near its 52-week peak of $14.89—combined with the director's historical track record showing a 100.00% well-timed sell rate across 13 prior open-market dispositions, raises material questions about capital preservation and near-term outlook. While stock performance in the 30 and 90 days post-transaction cannot yet be assessed, the velocity and timing of liquidation warrant investor attention given the underlying business deterioration.

ORBIMED ADVISORS LLC sells 868.7K shares (91.2% of holdings) for $11.5M at avg $13.24 amid revenue collapse

ORBIMED ADVISORS LLC, a Director, executed 4 separate sales totaling 868,682 shares for $11,497,963.08 over three trading days (Aug 21–23, 2024), reducing holdings from 952,377 shares to 83,695 shares. The sales occurred at prices ranging from $12.94 to $14.61 near the 52-week high of $14.89, while the current price is $12.96. Fundamentally, ARS Pharmaceuticals faces severe deterioration: annual revenue growth collapsed -97.7%, latest-quarter revenue stands at $500,000.00, and net income is negative $-12,516,000.00 with the company unprofitable over its most recent full fiscal year. Across the insider's cross-ticker track record, prior sells were well-timed 100% of the time with an average 90-day return of -26.1%, establishing a pattern of exits that preceded downward price action. This near-complete liquidation near the stock's 52-week highs coincides with a company experiencing operational distress and eroding fundamentals.